文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

高风险前列腺癌患者常规分割与低分割放疗(CHIRP):随机2期CHIRP试验的24个月患者报告结局

Conventional Versus Hypofractionated Radiation for High-Risk Prostate Cancer Patients (CHIRP): 24-Month Patient-Reported Outcomes of the Randomized Phase 2 CHIRP Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2022-05-07

随机2期CHIRP试验比较高风险前列腺癌常规分割放疗(78 Gy/39次)与低分割放疗(68 Gy/25次)的24个月患者报告结局,96例纳入生活质量分析(低分割组49例,常规分割组47例)。两组泌尿和性功能评分各时间点相似,常规分割组肠道困扰评分在3至18个月呈持续有利趋势且12个月时差异有统计学意义(P=0.016),低分割组SF-12躯体成分评分在6至18个月呈持续有利趋势且18个月时差异有统计学意义(P=0.017);24个月时两组生活质量评分无显著差异,早期差异不再存在。

要点

  • 24个月时常规分割与低分割放疗的患者报告生活质量无重大差异。
  • 肠道困扰评分在12个月时常规分割组更优(P=0.016),但24个月时差异不再存在。
  • SF-12躯体成分评分在18个月时低分割组更优(P=0.017),但24个月时差异不再存在。

核心结论

  • 放疗后24个月,常规分割与低分割放疗的患者报告生活质量无重大差异。
  • 肠道困扰和SF-12躯体成分评分的早期统计学显著差异在24个月时不再存在。

研究设计与样本

  • 随机2期CHIRP试验,高风险局限性前列腺癌男性随机接受常规分割放疗(78 Gy/39次)或低分割放疗(68 Gy/25次)。
  • 所有患者接受盆腔淋巴结放疗和辅助雄激素剥夺治疗。
  • 生活质量分析纳入96例参与者,低分割组49例,常规分割组47例。

主要发现

  • 泌尿和性功能评分在所有时间点两组相似。
  • 肠道困扰评分从治疗后3至18个月呈持续有利于常规分割组的趋势,12个月时差异有统计学意义(P=0.016)。
  • SF-12躯体成分评分从治疗后6至18个月呈持续有利于低分割组的趋势,18个月时差异有统计学意义(P=0.017)。
  • 24个月时两组生活质量评分无显著差异。

关键数值与推荐

  • 常规分割放疗剂量为78 Gy/39次,低分割放疗剂量为68 Gy/25次。
  • 生活质量数据通过扩展前列腺癌指数复合量表和简表12健康相关生活质量问卷在基线及治疗后3、6、12、18、24个月收集。
  • 采用独立t检验识别两组间差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In this study, we report the 24-month patient-reported outcomes of the randomized phase 2 CHIRP trial that compared conventional and hypofractionated radiation therapy (RT) in the treatment of high-risk prostate cancer. METHODS AND MATERIALS: Men with high-risk localized prostate cancer were randomized to either conventional (78 Gy/39 fractions) or hypofractionated RT (68 Gy/25 fractions). All patients received pelvic nodal RT and adjuvant androgen deprivation therapy. Quality of life (QoL) data were collected through the expanded prostate cancer index composite and the short-form 12 (SF-12) health-related QoL questionnaire at baseline and at 3, 6, 12, 18, and 24 months posttreatment. We assessed change from baseline to account for differences in baseline comorbidities. Independent t test was used to identify differences between the 2 groups. RESULTS: Ninety-six participants were included in the QoL analysis, 49 in the hypofractionation arm and 47 in the standard fractionation arm. Urinary and sexual scores were similar between the 2 arms at all time points. Bowel bother scores exhibited a consistent trend favoring the standard arm from 3- to 18-months posttreatment and were statistically significant at 12 months (P = .016). SF-12 physical component scores showed a consistent trend favoring the hypofractionation arm from 6- to 18-months posttreatment and were statistically significant at 18 months (P = .017). At 24 months, there were no significant differences in QoL scores between the 2 groups. CONCLUSIONS: At 24 months post-RT, there were no major differences in patient-reported QoL between standard and hypofractionated RT. Early statistically significant differences in bowel bother and SF-12 physical component scores were no longer present at 24 months.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Yang F, Ghosh S, Yee D, et al. Conventional Versus Hypofractionated Radiation for High-Risk Prostate Cancer Patients (CHIRP): 24-Month Patient-Reported Outcomes of the Randomized Phase 2 CHIRP Trial. Int J Radiat Oncol Biol Phys. 2022. PMID: 35537578. doi:10.1016/j.ijrobp.2022.04.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。